Obesity and Non-Valvular Atrial Fibrillation: An Unexpected Paradox | ||||
| Zagazig University Medical Journal | ||||
| Articles in Press, Accepted Manuscript, Available Online from 16 January 2024 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2024.253538.3034 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mahmoud Abdelsabour1; Christena Amir Bakhet  2; Salah Atta3
| ||||
| 1cardiology,faculty of medicine,Assiut university,Assiut ,Egypet | ||||
| 2cardiology ,faculty of medicine .Assiut university ,Assiut ,Egypet . | ||||
| 3cardiology department,faculty of medicine,Assiut university ,Assiut,Egypet | ||||
| Abstract | ||||
| Abstract Background: Obesity is believed to be one of the major cardiovascular morbidity and mortality risk factors. Furthermore, a strong link has been observed between obesity and atrial fibrillation , the most common cardiac arrhythmia. Objectives: To assess how obesity affects anticoagulation outcomes for bleeding and thrombotic incidents in patients with non-valvular atrial fibrillation and investigate the paradox of obesity in these patients. Results: Of the 300 cases, 105 were obese according to BMI. Besides obesity, hypertension, diabetes mellitus, smoking, dyslipidemia, CHA2DS2-VASc score, and the number of episodes were independent predictors for MACEs. Warfarin-treated non-obese patients had more complications than their obese counterparts. In contrast, the difference in complication rates among patients on DOACs was insignificant between the two groups. Conclusions: Non-valvular atrial fibrillation patients with obesity have a paradoxically lower risk of bleeding, stroke, and cardiovascular mortality on vitamin K antagonist treatment than non-obese patients. Keywords: Non-valvular Atrial Fibrillation, Obesity, MACEs. | ||||
| Keywords | ||||
| Keywords: Non-valvular Atrial Fibrillation; Obesity; MACEs | ||||
|
Statistics Article View: 68 |
||||
